Mupirocin is an antibacterial ointment used to treat impetigo and secondary skin infections caused by Staphylococcus aureus and Streptococcus pyogenes. Mupirocin, formerly termed pseudomonic acid A, is a novel antibacterial agent with a unique chemical structure and mode of action apart from other antibiotic agents.
- Mechanism
- Curator reviewed · 2 references
Mupirocin specifically and reversibly binds to bacterial isoleucyl transfer-RNA (tRNA) synthetase, which is an enzyme that promotes the conversion of isoleucine and tRNA to isoleucyl-tRNA. Inhibition of this enzyme subsequently leads to the inhibition of the bacterial protein and RNA synthesis. Mupirocin is bacteriostatic at lower concentrations but it exerts bactericidal effects with prolonged exposure, killing 90-99% of susceptible bacteria over a 24 hour period.
- Primary indication
- Indicated for the treatment of impetigo and secondary skin infections, leading to traumatic skin lesions, due to Staphylococcus aureus and Streptococcus pyogenes.Curator reviewed · 6 structured indications
- Formula / weight
- C26H44O9 · 500.6222 g/mol (avg)
- First approval
- Canada, 2001 · United States, 1996
- Also known as
- Pseudomonic acid · Pseudomonic acid A
- Code names
- BRL-4910A · BRL 4910F
- Brand names
Resolves to
MINDHVHHQZYEEK-HBBNESRFSA-NSMILESC[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Mupirocin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account